



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

4 93BR161

Reagent: vPE16

Catalog Number: 362

Lot Number:

Provided: 1 vial cell-free virus at 8×10^9 infectious virions/ml.

Host or Recommended Host or Host Cells: HeLa and other vertebrate cells.

Cloning Vector: Vaccinia virus, strain WR.

Description: The plasmid pPE16 was used to construct the recombinant virus. Expression is under control of the vaccinia virus P7.5 promoter. The two vaccinia virus termination signals (T₅NT) within the coding region of the *env* gene were altered by *in vitro* mutagenesis without changing the encoded amino acids. The entire *env* gene of HIV-1 (isolate HTLV-III_B, clone BH8) is expressed.

Special Characteristics: The *env* gene has been modified to eliminate cryptic vaccinia virus early transcriptional stop signals without altering coding sequences. Expresses gp160 which is glycosylated, processed into gp120 and gp41, and inserted into the plasma membrane. Cells infected with vPE16 will form syncytia with human CD4⁺ cells. vPE16 also expresses *E. coli* β -galactosidase. The control vaccinia viruses to this clone are available as catalog #353 and catalog #357.
Sterility: Negative for bacteria, fungi, and mycoplasma.
Cloning Site: Vaccinia virus thymidine kinase gene.

Recommended Storage: Liquid nitrogen.

Contributor: Dr. Patricia Earl and Dr. Bernard Moss.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References:

Earl PL, Hugin A, Moss B. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type I envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus. *J Virol* **64**:2448-2451, 1990.
Earl PL, Koenig S, Moss B. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses. *J Virol* **65**:31-41, 1991.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: vPE16 from Dr. Patricia Earl and Dr. Bernard Moss." Please include the references cited above in any publications.

The US Government has submitted a patent application on this reagent.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact Dr. Sally Hu at the NIH Office of Technology Transfer, Email: hus@mail.nih.gov, Phone: 301-435-5606, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.

Last Updated:

June 24, 2013

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.